Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 26.40% and Operating profit at 63.15% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 1.36% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 26.40% and Operating profit at 63.15% over the last 5 years
3
The company has declared Positive results for the last 5 consecutive quarters
4
With ROE of 3.77%, it has a expensive valuation with a 4.10 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,750 Million (Mid Cap)
109.00
NA
0.19%
0.01
3.77%
4.93
Revenue and Profits:
Net Sales:
286 Million
(Quarterly Results - Jun 2026)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.57%
0%
4.57%
6 Months
-10.2%
0%
-10.2%
1 Year
-19.42%
0%
-19.42%
2 Years
72.19%
0%
72.19%
3 Years
14.84%
0%
14.84%
4 Years
22.32%
0%
22.32%
5 Years
-32.31%
0%
-32.31%
Shenzhen Chipscreen Biosciences Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
26.40%
EBIT Growth (5y)
63.15%
EBIT to Interest (avg)
-1.20
Debt to EBITDA (avg)
0.92
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.23
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
46.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.03%
ROE (avg)
1.36%
Valuation key factors
Factor
Value
P/E Ratio
109
Industry P/E
Price to Book Value
4.10
EV to EBIT
78.77
EV to EBITDA
56.03
EV to Capital Employed
4.07
EV to Sales
10.58
PEG Ratio
0.59
Dividend Yield
0.22%
ROCE (Latest)
5.17%
ROE (Latest)
3.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
286.20
244.30
17.15%
Operating Profit (PBDIT) excl Other Income
79.50
70.80
12.29%
Interest
10.60
7.60
39.47%
Exceptional Items
0.70
-0.00
Consolidate Net Profit
43.10
48.70
-11.50%
Operating Profit Margin (Excl OI)
208.80%
215.80%
-0.70%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 17.15% vs 44.13% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -11.50% vs 314.54% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
907.50
655.80
38.38%
Operating Profit (PBDIT) excl Other Income
155.30
0.90
17,155.56%
Interest
35.80
34.40
4.07%
Exceptional Items
0.20
-90.00
100.22%
Consolidate Net Profit
51.00
-114.60
144.50%
Operating Profit Margin (Excl OI)
90.80%
-92.40%
18.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 38.38% vs 27.14% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 144.50% vs -332.93% in Dec 2024
About Shenzhen Chipscreen Biosciences Co., Ltd. 
Shenzhen Chipscreen Biosciences Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






